Vertex Pharmaceuticals Incorporated (VRTX)
| Market Cap | 123.26B +2.2% |
| Revenue (ttm) | 12.22B +10.1% |
| Net Income | 4.34B |
| EPS | 16.86 |
| Shares Out | 253.81M |
| PE Ratio | 28.80 |
| Forward PE | 25.50 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,568,036 |
| Open | 483.51 |
| Previous Close | 486.03 |
| Day's Range | 481.98 - 496.69 |
| 52-Week Range | 362.50 - 533.67 |
| Beta | 0.29 |
| Analysts | Buy |
| Price Target | 556.24 (+14.54%) |
| Earnings Date | Aug 3, 2026 |
About VRTX
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMK... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 30 analysts, the average rating for VRTX stock is "Buy." The 12-month stock price target is $556.24, which is an increase of 14.54% from the latest price.
News
Vertex Pharmaceuticals price target raised to $585 from $545 at UBS
UBS raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $585 from $545 and keeps a Buy rating on the shares.
Vertex Pharmaceuticals price target raised to $560 from $542 at Truist
Truist raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $560 from $542 and keeps a Buy rating on the shares as part of a broader research note previewing…
Vertex Pharmaceuticals price target raised to $600 from $598 at BofA
BofA raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $600 from $598 and keeps a Buy rating on the shares. The firm is bullish on the strength of…
How to Ride the $2.6 Trillion Merger Boom With High-Growth Stocks
More mergers among brand-name consumer companies seem likely—following a record $2.6 trillion worth of transactions announced in the first half of 2026.
Crinetics downgraded to Hold from Buy at TD Cowen
TD Cowen analyst Tyler Van Buren downgraded Crinetics (CRNX) to Hold from Buy with no price target after Vertex Pharmaceuticals (VRTX) announced an agreement to acquire the the company for…
Vertex to Announce Second Quarter 2026 Financial Results on August 3rd
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2026 financial results on Monday, August 3, 2026, after the financial markets close. The comp...
Wedbush sees BioCryst, Ascendis as potential next targets after Crinetics deal
Wedbush notes that Vertex Pharmaceuticals (VRTX) agreed to acquire Crinetics Pharmaceuticals (CRNX) for $85/share in cash. Crinetics now trades essentially at the deal price, reflecting high confidenc...
Crinetics shares surge after Vertex agrees to $10B cash buyout
Crinetics Pharmaceuticals shares surged after Vertex Pharmaceuticals announced an agreement to acquire the endocrinology-focused biotech company in a deal valued at approximately $10 billion. The all-...
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Crinetics Pharmaceuticals, Inc. (CRNX)
Bala Cynwyd, Pennsylvania--(Newsfile Corp. - July 7, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Crinetics Pharmaceutica...
Vertex adds ‘genuine fifth commercial pillar’ with deal, says H.C. Wainwright
After Vertex Pharmaceuticals’ (VRTX) announcement of an agreement to acquire Crinetics (CRNX) for $85 per share in cash, H.C. Wainwright analyst Andrew Fein thinks “the most important question” is wha...
This Biotech Stock Is Soaring 99% After Vertex Agrees to Takeover Deal
Vertex Pharmaceuticals is buying an endocrine treatment specialist for $10 billion.
Vertex Pharmaceuticals price target raised to $570 from $543 at RBC Capital
RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $570 from $543 and keeps an Outperform rating on the shares as part of a broader research note…
Vertex Pharmaceuticals price target raised to $350 from $330 at Baird
Baird raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $350 from $330 and keeps an Underperform rating on the shares. The firm updated its model after the company…
Crinetics price target raised to $85 from $62 at Baird
Baird raised the firm’s price target on Crinetics (CRNX) to $85 from $62 and keeps an Outperform rating on the shares. The firm updated its model after Vertex Pharmaceuticals (VRTX)…
Crinetics downgraded to Perform from Outperform at Oppenheimer
Oppenheimer downgraded Crinetics (CRNX) to Perform from Outperform with no price target after Vertex Pharmaceuticals (VRTX) announced an agreement to acquire the company for $85 per share in cash. The...
Why Is Crinetics Stock (CRNX) Surging Nearly 100% in Pre-Market Today, 7/7/26? Analysts React
Crinetics Pharmaceuticals ($CRNX) stock surged nearly 100% in pre-market trading on Tuesday after Vertex Pharmaceuticals ($VRTX) agreed to acquire the biotech company in a deal valued at about $10 bil...
M&A News: Vertex Stock (VRTX) Slips After Announcing the $10B Crinetics Acquisition
Vertex Pharmaceuticals ($VRTX) fell about 2.3% after hours on Monday following a deal to acquire endocrine‑focused drugmaker Crinetics Pharmaceuticals ($CRNX) for $10 billion, or $85 per share in cash...
Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion
The acquisition would add to Vertex's pipeline and potentially grow its annual revenue by $5 billion with the addition of Crinetics-developed drugs Palsonify and Atumelnant, the company said.
Vertex Pharmaceuticals Transcript: M&A announcement
Vertex will acquire Crinetics for $85/share in cash (~$10B equity value), adding best-in-class endocrine assets PALSONIFY and atumelnant. The deal diversifies Vertex's portfolio, is expected to deliver over $5B in peak sales, and will be accretive to operating income by 2029.
Vertex Pharmaceuticals Press release: M&A announcement
Vertex Pharmaceuticals issued a press release on July 6, 2026, disclosing material business information to investors.
Vertex Pharmaceuticals Slides: M&A announcement
Vertex Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on July 6, 2026.
Vertex to acquire Crinetics for $85 per share in cash
Vertex Pharmaceuticals Incorporated (VRTX) and Crinetics Pharmaceuticals, Inc. (CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics...
Vertex to buy Crinetics in $10 billion deal
Vertex Pharmaceuticals will buy Crinetics Pharmaceuticals for a total equity value of about $10 billion, the companies said on Monday.
Vertex to Acquire Crinetics Pharmaceuticals
BOSTON & SAN DIEGO--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, de...
Vertex enters LOI with pan-Canadian Pharmaceutical Alliance for ALYFTREK
Vertex Pharmaceuticals (VRTX) signed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance for ALYFTREK, a new triple combination therapy for the treatment of cystic fibrosis in patients ag...